Regeneron Pharmaceuticals Stock News

In the latest trading session, Regeneron (REGN) closed at $693.20, marking a +1.06% move from the previous day.

There are reasons to like Amgen that go beyond its market-beating 3.4% dividend yield.

Regeneron (REGN) closed the most recent trading day at $665.93, moving +1.45% from the previous trading session.

Regeneron (REGN) closed the most recent trading day at $665.93, moving +1.45% from the previous trading session.

Astrazeneca PLC found using ticker (AZN) have now 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 70 and 59.5 calculating the average target price we see 66.98. Given that the stocks previous close was at 60.9 this now indicates there is a potential upside of 10.0%. The day 50 moving average is 58.73 and the 200 moving average now moves to 58.51. The market cap for the company is $188,315m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets=AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $207,116m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Regeneron (REGN) closed the most recent trading day at $642.58, moving +1.94% from the previous trading session.

U.S. Indices finished lower Friday amid continued uncertainty from the Russia-Ukraine conflict. The Nasdaq composite finished lower by 2.18% to 12,843; The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) lo

Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.

It's not all smooth sailing for this drugmaker.

Stocks Cap Another Losing Week: Regeneron Flashes Buy Signals; Harmony, Builders FirstSource Set Up Investor's Business Daily has been helping people invest smarter results by providing exclusive stoc

It's not all smooth sailing for this drugmaker.

Regeneron Pharmaceuticals rejoins the IBD 50 hot stocks to watch as it builds a new base and could break out.

Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.

Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.

Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.